Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Birgit Schoeberl

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Frontiers in Pharmacology|May 2, 2022
Navigating Between Right, Wrong, and Relevant: The Use of Mathematical Modeling in Preclinical Decision MakingAnna Kondic, Dean Bottino, John Harrold, et al.
BMC Biology|March 25, 2014
Analysis of growth factor signaling in genetically diverse breast cancer linesMario Niepel, Marc Hafner, Emily A Pace, et al.
NPJ Systems Biology and Applications|September 26, 2017
Predicting ligand-dependent tumors from multi-dimensional signaling featuresHelge Hass, Kristina Masson, Sibylle Wohlgemuth, et al.
Molecular Cancer Therapeutics|May 9, 2012
Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodiesYu Zhou, Anne-Laure Goenaga, Brian D Harms, et al.
Mabs|February 9, 2013
Rapid optimization and prototyping for therapeutic antibody-like moleculesLihui Xu, Neeraj Kohli, Rachel Rennard, et al.
Therapeutic Innovation & Regulatory Science|May 29, 2025
The Adoption and Use of Artificial Intelligence and Machine Learning in Clinical DevelopmentMary Jo Lamberti, Maria I Florez, Hana Do, et al.
Scientific Reports|November 16, 2019
Dual targeting of IGF-1R and ErbB3 as a potential therapeutic regimen for ovarian cancerAdam J Camblin, Gege Tan, Michael D Curley, et al.
Plos Computational Biology|August 28, 2020
Ten simple rules to power drug discovery with data scienceEnrico Ferrero, Sophie Brachat, Jeremy L Jenkins, et al.
Cancer Research|March 11, 2010
An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activationBirgit Schoeberl, Anthony C Faber, Danan Li, et al.
Molecular Cancer Therapeutics|January 18, 2012
Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3Charlotte F McDonagh, Alexandra Huhalov, Brian D Harms, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Frontiers in Pharmacology|May 2, 2022
Navigating Between Right, Wrong, and Relevant: The Use of Mathematical Modeling in Preclinical Decision MakingAnna Kondic, Dean Bottino, John Harrold, et al.
BMC Biology|March 25, 2014
Analysis of growth factor signaling in genetically diverse breast cancer linesMario Niepel, Marc Hafner, Emily A Pace, et al.
NPJ Systems Biology and Applications|September 26, 2017
Predicting ligand-dependent tumors from multi-dimensional signaling featuresHelge Hass, Kristina Masson, Sibylle Wohlgemuth, et al.
Molecular Cancer Therapeutics|May 9, 2012
Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodiesYu Zhou, Anne-Laure Goenaga, Brian D Harms, et al.
Mabs|February 9, 2013
Rapid optimization and prototyping for therapeutic antibody-like moleculesLihui Xu, Neeraj Kohli, Rachel Rennard, et al.
Therapeutic Innovation & Regulatory Science|May 29, 2025
The Adoption and Use of Artificial Intelligence and Machine Learning in Clinical DevelopmentMary Jo Lamberti, Maria I Florez, Hana Do, et al.
Scientific Reports|November 16, 2019
Dual targeting of IGF-1R and ErbB3 as a potential therapeutic regimen for ovarian cancerAdam J Camblin, Gege Tan, Michael D Curley, et al.
Plos Computational Biology|August 28, 2020
Ten simple rules to power drug discovery with data scienceEnrico Ferrero, Sophie Brachat, Jeremy L Jenkins, et al.
Cancer Research|March 11, 2010
An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activationBirgit Schoeberl, Anthony C Faber, Danan Li, et al.
Molecular Cancer Therapeutics|January 18, 2012
Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3Charlotte F McDonagh, Alexandra Huhalov, Brian D Harms, et al.
Pageof 4